2QB0 Stock Chart & Stats
€0.24
-€0.01(-5.60%)
At close: 4:00 PM EDT
€0.24
-€0.01(-5.60%)
Day’s Range― - ―
52-Week Range€0.20 - €1.06
Previous CloseN/A
Volume0.00
Average Volume (3M)1.90K
Market Cap
€36.99M
Enterprise Value€37.05M
Total Cash (Recent Filing)€436.82K
Total Debt (Recent Filing)€5.70M
Price to Earnings (P/E)―
Beta-0.44
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding141,782,420
10 Day Avg. Volume100
30 Day Avg. Volume1,903
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Ophthalmic Product StrategyA clearly defined focus on ophthalmic innovation can concentrate limited resources, technical expertise and commercialization planning around one identifiable product opportunity.
Intellectual Property DevelopmentOngoing intellectual-property work may help establish defensibility around the lens platform and support future partnering, licensing or market-entry opportunities if development succeeds.
Regulatory And Commercialization PlanningRegulatory and commercialization planning indicates that management is addressing the key pathways needed to translate the technology from development into a potentially marketable ophthalmic product.
Bears Say
No Revenue And Worsening LossesThe absence of revenue and widening losses show that the business has not yet achieved commercial traction or positive gross economics, increasing dependence on successful development and future financing.
Persistent Cash BurnSustained operating and free-cash-flow deficits indicate continuing funding requirements. Without revenue growth or improved profitability, cash resources may remain under pressure over the medium term.
Negative Equity And Rising DebtRising debt combined with deeply negative equity and a small asset base signals constrained financial flexibility, elevating refinancing, dilution and solvency risks while development continues.
2QB0 FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was €0.20 and its highest was €1.06 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is €36.99M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Sep 01, 2026 which is in 11 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 141,782,420 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in DE:2QB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―






